Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.59 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133010 | 0.89 | CRBN (0.56) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL25933163 | 0.88 | CRBN (0.49) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20128628 | 0.80 | CRBN (0.51) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL17173836 | 0.80 | CRBN (0.63) | CRBNIKZF3DDB1TNFIL1B | |
| SCHEMBL20128661 | 0.80 | CRBN (0.64) | CRBNIKZF3DDB1BRD4TNF | |
| Quinoline SCHEMBL27606599 | 0.79 | CRBN (0.74) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL23660923 | 0.79 | CRBN (0.60) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL476917 | 0.79 | CRBN (1.00) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL19556664 | 0.79 | CRBN (1.00) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL19556665 | 0.79 | CRBN (1.00) | CRBNIKZF3DDB1BRD4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | CRBN 1/4885IKZF3 463/4885DDB1 171/4885 |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | CRBN 3240/4885IKZF3 3819/4885DDB1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.